Quoin Pharmaceuticals, Ltd.
QNRX
$7.20
-$0.0796-1.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.74M | 1.58M | 1.33M | 1.36M | 1.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.79M | 3.96M | 2.41M | 2.53M | 2.14M |
| Operating Income | -3.79M | -3.96M | -2.41M | -2.53M | -2.14M |
| Income Before Tax | -3.70M | -3.81M | -2.31M | -2.35M | -1.97M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.70M | -3.81M | -2.31M | -2.35M | -1.97M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.70M | -3.81M | -2.31M | -2.35M | -1.97M |
| EBIT | -3.79M | -3.96M | -2.41M | -2.53M | -2.14M |
| EBITDA | -3.77M | -3.93M | -2.38M | -2.50M | -2.11M |
| EPS Basic | -219.93 | -227.56 | -432.82 | -570.05 | -478.87 |
| Normalized Basic EPS | -3.93 | -4.06 | -7.73 | -10.18 | -8.55 |
| EPS Diluted | -220.50 | -227.56 | -434.36 | -575.75 | -478.87 |
| Normalized Diluted EPS | -3.93 | -4.06 | -7.73 | -10.18 | -8.55 |
| Average Basic Shares Outstanding | 588.20K | 586.30K | 186.90K | 144.30K | 144.30K |
| Average Diluted Shares Outstanding | 16.80K | 16.70K | 5.30K | 4.10K | 4.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |